Vir Biotechnology第四季度每股收益$(0.76)优于预期$(0.87),销售额$12.37M优于预期$8.14M

财报速递2025-02-27
Vir Biotechnology (NASDAQ:VIR)报告季度每股亏损$(0.76),优于分析师普遍预期的$(0.87),增长了12.64%。较去年同期的每股亏损$(0.86)提高了11.63%。公司报告季度销售额为$12.37M,超过了分析师普遍预期的$8.14M,增长了52.01%。与去年同期的销售额$16.79M相比,减少了26.29%。

以上内容来自Benzinga Earnings专栏,原文如下:

Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.87) by 12.64 percent. This is a 11.63 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $12.37 million which beat the analyst consensus estimate of $8.14 million by 52.01 percent. This is a 26.29 percent decrease over sales of $16.79 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法